| DC7540 |
SIRT2 Inhibitor II, AK-7
Featured
|
AK-7 is a cell- and brain-permeable inhibitor of SIRT2 (IC50 = 15.5 μM). |
|
| DC23789 |
AK778
Featured
|
AK778 (Col001) is a small-molecule compound that inhibits the interaction of Hsp47 with collagen, competitively inhibits the interaction and causes the inhibition of collagen secretion by destabilizing the collagen triple helix. . |
|
| DC20649 |
AKB-9778
Featured
|
AKB-9778 is a potent, selective inhibitor of vascular endothelial protein tyrosine phosphatase (VE-PTP) with IC50 of 17 pM. |
|
| DC12158 |
AKOS B018304
Featured
|
AKOS B018304 is an arylalkylidene derivative, with polar substitution at para-position. |
|
| DC8458 |
Akt Inhibitor VIII
Featured
|
Akt Inhibitor VIII is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit Akt1, Akt2, and Akt3 activity (IC50 = 58 nM, 210 nM, and 2.12 μM; respectively). |
|
| DC9677 |
AL 082D06(D-06)
Featured
|
AL 082D06(D-06) is the first selective, nonsteroidal glucocorticoid receptor (GR) antagonist with Ki of 210 nM, exhibits excellent selectivity against AR, PR, MR and ER(Ki > 10 uM). |
|
| DC20260 |
AL-335
Featured
|
AL-335 is a potent inhibitor of hepatitis C virus (HCV) NS5B polymerase with IE50 values as low as 70 nM. AL-335 is potentially useful for the Treatment of Hepatitis C Infection. AL-335 demonstrated high levels of the nucleoside triphosphate in vitro in primary human hepatocytes and Huh-7 cells as well as in dog liver following a single oral dose. AL-335 was selected for the clinical development where it showed promising results in phase 1 and 2 trials. |
|
| DC10780 |
ALB-127158(a)
Featured
|
ALB-127158A, also known as ALB-127158(a), is a MCH1 antagonist for the treatment of obesity. |
|
| DC20174 |
Albiglutide
Featured
|
Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist). |
|
| DC8723 |
Alda-1
Featured
|
Alda-1 is an ALDH2 agonist, cell-permeable activator of both the wild-type ALDH2*1 and the asian E487K mutant ALDH2*2 forms of mitochondrial aldehyde dehydrogenase 2 (mtALDH2). |
|
| DC20653 |
ALE-0540
Featured
|
ALE-0540 is a nerve growth factor (NGF) antagonist that inhibits the binding of NGF to TrkA or both p75 and TrkA with IC50 of 5.88 and 3.72 uM, respectively. |
|
| DC22492 |
Alexamorelin
Featured
|
Alexamorelin is a synthetic growth hormone (GH) secretagogue. |
|
| DC12389 |
Alflutinib
Featured
|
Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.The Alflutinib free base form is not stable, so we make it the mesylate s |
|
| DC12072 |
Alflutinib (AST2818 mesylate)
Featured
|
Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.. |
|
| DC22211 |
ALG1001 (Risuteganib)
Featured
|
ALG1001 (Risuteganib, ALG-1001) is a first-in-class, RGD class oligopeptide that inhibits integrin receptors (αvβ3, αvβ5, and α5β1) associated with angiogenesis; ALG1001 inhibits an integrin-mediated pathway of the vitreoretinal interface, connecting the posterior aspect of the vitreous with the internal limiting membrane of the retina. In blocking this pathway, ALG-1001 helps to achieve vitreous breakdown and separation from the retina. |
|
| DCAPI1495 |
Aliskiren Hemifumarate
Featured
|
Aliskiren hemifumarate(CGP 60536) is a direct renin inhibitor with IC50 of 1.5 nM. |
|
| DC9338 |
ALK inhibitor 1
Featured
|
ALK inhibitor 1 is a novel and selective inhibitor for the ALK kinase. |
|
| DC9339 |
ALK inhibitor 2
Featured
|
ALK inhibitor 2 is a novel and selective inhibitor for the ALK kinase. |
|
| DC10582 |
Diroximel Fumarete(ALKS-8700)
Featured
|
ALKS-8700 also known as diroximel fumarate, is a prodrug of monomethyl fumarate in a controlled-release formulation that rapidly and efficiently converts to MMF in the body. |
|
| DC11495 |
Allitinib
Featured
|
Allitinib (AST-1306, ALS1306)) is a novel potent, selective irreversible EGFR and HER2 inhibitor with IC50 of 0.5 and 3 nM in cell-free assays. |
|
| DC8570 |
ALLO-1
Featured
|
ALLO-1 is a SMO antagonist that inhibits both wild-type (IC50 = 50 nM) and mutant SMO, including the D473H SMO mutant (IC50s = 300-1000 nM). |
|
| DC21668 |
ALLO-2
Featured
|
ALLO-2 is a potent small molecule Smoothened (Smo) antagonist that inhibits Smo agonist Hh-Ag1.5-induced luciferase expression in TM3-Gli-Luc cells with IC50 of 6 nM. |
|
| DC10311 |
Allopregnanolone
Featured
|
Allopregnanolone is a progesterone metabolite. Allopregnanolone is an allosteric modulator of the GABA receptor. |
|
| DCAPI1097 |
Allopurinol Sodium (Aloprim)
Featured
|
Allopurinol sodium is a potent xanthine oxidase inhibitor (IC50 values of 0.2 to 50 μM). Allopurinol sodium can be used for the research of hyperuricemia and gout. Antileishmanial effect[1][2]. |
|
| DC7692 |
Almorexant HCl (Act-078573)
Featured
|
Almorexant(ACT078573) is a potent and competitive dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist with Ki values of 1.3 and 0.17 nM for OX1 and OX2, respectively. |
|
| DC8284 |
Almotriptan Malate(PNU180638)
Featured
|
Almotriptan Malate is a 5-HT1B/1D-receptor agonist used to treat migraine. |
|
| DC11887 |
Alobresib (GS-5829)
Featured
|
Alobresib is a novel BET bromodomain inhibitor with antineoplastic activity.. |
|
| DC11931 |
Alofanib
Featured
|
Alofanib ((RPT-835) is a potent, selective, allosteric FGFR2 inhibitor that significantly inhibits bFGF-induced proliferation of HUVEC cells with IC50 of 11 nM |
|
| DC5076 |
Alogliptin Benzoate
Featured
|
Alogliptin is an orally administered, anti-diabetic drug in the DPP-4 inhibitor class. A randomized clinical trial reporting in 2011 aimed to determine the efficacy and safety of alogliptin versus placebo and voglibose among newly diagnosed Type 2 diabete |
|
| DC10735 |
Alovudine
Featured
|
Alovudine is a DNA polymerase subunit gamma-1 (POLG) inhibitor, shows promise for treating AML. |
|
